Parkinson’s disease is a chronic neurodegenerative disease characterized by progressively worsening motor symptoms. Treatment of Parkinson’s disease in China comprises a broad range of…
The market for NASH, a severe form of nonalcoholic fatty liver disease (NAFLD), offers substantial commercial opportunity to drug developers owing to the lack of approved agents and the disease’s…
Heart failure presents a major public health burden in China. With a rapidly rising urban population and a growing trend of unhealthy lifestyle, heart failure is expected to affect a sizeable…
Heart failure presents a major public health burden in China. With a rapidly rising urban population and a growing trend of unhealthy lifestyle, heart failure is expected to affect a sizeable…
Heart failure (HF) is classified as acute or chronic, and both settings are the focus of this report. Although much progress has been made in the pharmacological management of HF, it mainly relates…
Beta thalassemia (BT) is a rare genetic disorder characterized by the reduced production of hemoglobin. It is caused by a mutation in one hemoglobin beta (HBB) gene (beta thalassemia minor) or a…
Beta thalassemia (BT) is a rare genetic disorder characterized by the reduced production of hemoglobin. It is caused by a mutation in one hemoglobin beta (HBB) gene (beta thalassemia minor) or a…
MARKET OUTLOOK TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while non-TNF biologics…
Over the past two decades, in response to mounting failures, clinical trials of disease-modifying therapies (DMTs) in Alzheimer’s disease (AD) have moved earlier in the disease spectrum to…
Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s…
MARKET OUTLOOK First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, and an oral diuretic. The addition of a…
MARKET OUTLOOK First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, and an oral diuretic. The addition of a…
Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s…
Children with Crohn’s disease (CD) have a more-complicated disease course compared with adult patients. Historically, treatment of pediatric CD would begin with safe, albeit often less-…